297 results about "Combination chemotherapy" patented technology

The present invention relates to photosensitizer immunoconjugate compositions and combination therapies for use in cancer related photodynamic treatments and diagnostic methods. Photosensitizer immunoconjugates comprising a photosensitizer conjugated to a tumor-specific and / or tumoricidial antibody and processes for the preparation thereof are described. The use of photosensitizer immunoconjugates (PICs) offers improved photosensitizer delivery specificity for diagnostic and therapeutic applications. Combination therapies to co-localize activated photosensitizer compounds and tumoricidal antibodies in tumor tissues are also described.

The present invention provides a novel therapeutic combination comprising one or more anti-androgen agents and one or more antibiotic / anti-inflammatory agents or pharmaceutically acceptable salts or hydrates thereof, useful for the treatment of a dermatological disorder.

The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that inhibits a pro survival and / or inflammatory signal.

Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.

The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system. The methods comprise administering a nitrated lipid in combination with an inhibitor of the renin-angiotensin-aldosterone system to a subject in need thereof, in an amount effective to treat diabetic nephropathy, chronic kidney disease, and / or end-stage renal disease. The use of a nitrated lipid with an inhibitor of the renin-angiotensin-aldosterone system exhibits a synergistic effect in treating chronic kidney disease and diabetic nephropathy.

The present invention relates to the technical field of nanometer selenium hydrosols, particularly to a nanometer selenium hydrosol having antitumor activity, a preparation method, a preservation method and applications thereof, wherein the hydrosol at least contains nanometer selenium with a concentration of 0.5-5.0 mmol / L, and Coriolus versicolor polysaccharide protein with a concentration of 100.0-600.0 mg / L. The preparation method at least comprises: S01, adding a solution containing selenium ions and / or selenous ions to a Coriolus versicolor polysaccharide protein aqueous solution; S02, adding a reducing agent solution to the mixed solution obtained in the step S01 in a dropwise manner, and shaking; and S03, carrying out volume metering on the product obtained after the reducing reaction, and carrying out dialysis treatment. According to the present invention, the hydrosol is stable at a temperature of 2-10 DEG C; and the Coriolus versicolor polysaccharide protein has the hydrophilic hydroxyl and the hydrophilic amino, and the two groups can enhance the affinity between the nanometer selenium and the cancer cells, and can improve the uptake on the nanometer selenium by tumor cells so as to achieve the whole treatment effect of medication dosage reducing, treatment effect improving and less toxic-side effect, such that the effective scheme is provided for the combination chemotherapy of cancers in the clinic.

Compositions comprising the combination of a membrane active biocide and a second agent selected from fluoroquinolones, ammoglycodies, ss-lactams, glycopeptide antibiotics, sufonamides and antifungal azoles and their use in the treatment or prevention of bacterial or fungal infections Preferred membrane active biocides are selected from chlorohexidme, polymyxin B-nonapeptide, bacitracin, aztreonam, benzlakomum salts and metal chelators The active ingredients can be in either monomer or polymeric form.